PDS Biotechnology (NASDAQ:PDSB) Releases Earnings Results, Beats Estimates By $0.02 EPS

PDS Biotechnology (NASDAQ:PDSB) issued its earnings results on Wednesday. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02, FiscalAI reports.

Here are the key takeaways from PDS Biotechnology’s conference call:

• PDS Biotechnology amended VERSATILE-003 to use progression-free survival as an interim primary endpoint, which management believes could speed an accelerated approval path and shorten the trial’s duration.
• The company said the amended design also reduces costs by lowering the trial size from about 350 patients to 250 and changing the randomization ratio to 1:1:1.
• Management highlighted continued momentum in PDS0101, saying the therapy remains a differentiated late-stage option in HPV-16 positive head and neck cancer because it is subcutaneous and requires only five doses.
• The company reported encouraging updates from its PDS01ADC program in both colorectal and prostate cancer, including published biomarker data and early clinical results that support broader immuno-oncology potential.
• First-quarter 2026 results showed a net loss of $7.3 million versus $8.5 million a year ago, with cash of $21.7 million at quarter-end and lower operating expenses year over year.

PDS Biotechnology Stock Performance

NASDAQ:PDSB traded up $0.23 during trading on Wednesday, reaching $1.33. The company’s stock had a trading volume of 1,370,396 shares, compared to its average volume of 1,065,793. The company has a quick ratio of 2.98, a current ratio of 2.98 and a debt-to-equity ratio of 1.27. The firm has a 50 day moving average of $0.87 and a 200-day moving average of $0.86. PDS Biotechnology has a 12 month low of $0.51 and a 12 month high of $1.92.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in PDS Biotechnology in the 4th quarter valued at $25,000. Marshall Wace LLP bought a new position in PDS Biotechnology in the 2nd quarter valued at $91,000. Jane Street Group LLC bought a new position in PDS Biotechnology in the 2nd quarter valued at $92,000. Susquehanna International Group LLP grew its stake in PDS Biotechnology by 603.7% in the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares during the period. Finally, Commonwealth Equity Services LLC grew its stake in PDS Biotechnology by 117.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after purchasing an additional 106,300 shares during the period. Institutional investors own 26.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PDSB. Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of PDS Biotechnology in a research report on Wednesday, April 15th. Finally, Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.